News
Sports
Life
Opinion
Business
Advertise
Obituaries
eNewspaper
Legals
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
NewsOK Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Gilead Sciences, Inc.
< Previous
1
2
3
4
5
6
7
8
9
Next >
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
November 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023
November 02, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer
October 31, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
October 24, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV
October 20, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities
October 19, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
October 18, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
October 17, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
ASMB
GILD
Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023
October 16, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023
October 16, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
October 12, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
October 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders
October 02, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
September 19, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
September 18, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer
September 10, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Prices $2 Billion of Senior Unsecured Notes
September 07, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
August 24, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Present at Upcoming Investor Conferences
August 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
August 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
August 18, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
August 15, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces Second Quarter 2023 Financial Results
August 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
July 27, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
July 24, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic
July 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
July 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
July 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
July 20, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
July 19, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.